-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-08-21
The reference study identifies Cdc2-like kinase 2 (CLK2) as a determinant of platinum resistance in ovarian cancer and links this phenotype to CLK2-mediated phosphorylation of BRCA1 at Ser1423. Its combination of patient-tissue profiling, functional assays, xenograft validation, and mechanistic analysis supports CLK2 as a candidate vulnerability while also defining important limits for pharmacologic translation.
-
SB743921: KSP Inhibition for Cancer Assays
2026-08-20
SB743921 enables selective KSP-driven mitotic perturbation in cancer research, from dose–response screening to mechanism-resolved viability studies. Its greatest practical value emerges when cell cycle arrest, proliferation slowdown, and cell death are measured as distinct outcomes rather than collapsed into one readout.
-
Bufuralol Hydrochloride in β-Adrenergic Research
2026-08-20
Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity. Its receptor pharmacology supports cardiovascular pharmacology research, while human iPSC-derived intestinal organoids provide a separate framework for absorption, metabolism, and pharmacokinetic studies.
-
Jasplakinolide: Designing Better Actin Assays
2026-08-19
Jasplakinolide is an actin polymerization inducer that can reveal how filament formation and stabilization reshape cell behavior. This guide focuses on assay design, interpretation, controls, and the chemical-genetic lessons that distinguish mechanistic evidence from a merely visible cytoskeletal phenotype.
-
From Exosomal Wnt10a to Translational Readouts
2026-08-18
Lithium-driven exosomal Wnt10a secretion offers a mechanistic framework for improving osteogenesis, but translational progress depends on rigorous, scalable readouts. This article connects Rab11a-dependent exosome trafficking with practical fluorescent detection strategies using a Cy5-conjugated secondary antibody in mouse antibody-based assays.
-
(-)-JQ1: The Control That Makes BET Data Translational
2026-08-18
(-)-JQ1, the JQ1 stereoisomer that lacks significant bromodomain engagement, is more than an inactive comparator. Used beside active JQ1, vehicle, and genetic controls, it can strengthen epigenetics research, cancer biology research, and translational decisions involving BRD4 biology.
-
PDA Chemotherapeutic Screening: Rgs16::GFP and JQ1
2026-08-17
Layeghi-Ghalehsoukhteh and colleagues developed a concerted cell-culture and in vivo screening strategy for pancreatic ductal adenocarcinoma using Rgs16::GFP as a rapid pharmacodynamic reporter. The study showed that trichostatin A, gemcitabine, and JQ1 produced complementary activity in culture and that their combination suppressed tumor initiation and progression in mouse models, while also highlighting the need to distinguish active JQ1 from its inactive stereoisomer in control experiments.
-
Recombinant Human IL-15 for Neuroimmune Assays
2026-08-17
Recombinant Human IL-15 offers a controlled way to investigate immune-cell responsiveness alongside neural threat-processing phenotypes. This article explains how to use IL-15 without overstating its relationship to oxytocin signaling in early life adversity research.
-
Annexin V-FITC/PI Apoptosis Assay Kit Workflow
2026-08-16
Build a reproducible apoptosis assay for separating viable, early apoptotic, late apoptotic, and necrotic cells by flow cytometry or fluorescence microscopy. This workflow also shows how to evaluate host-cell tolerability when studying targeted antimicrobial nanotherapeutics for infected wounds.
-
(-)-JQ1: The Control That Makes BET Biology Credible
2026-08-15
A translational framework for using (-)-JQ1 as a stereochemical negative control when interpreting BET inhibition, BRD4-dependent transcription, and heterogeneous responses in HPV-associated head and neck cancer models.
-
Programmed Cell Death Mechanisms in Heart Disease
2026-08-14
Konstantinidis, Whelan, and Kitsis synthesize evidence that apoptosis and necrosis are mechanistically connected, regulated processes that contribute to myocardial infarction and heart failure. The review’s principal implication is that defining pathway-specific cell-death decisions may support more precise experimental designs and identify small-molecule intervention points.
-
Latrunculin B: Actin Dynamics Workflow Guide
2026-08-14
Latrunculin B enables controlled, short-duration actin filament assembly inhibition for imaging, cytoskeletal organization studies, and mechanistic perturbation. Its transient behavior also makes it a valuable negative control when testing whether a cellular entry process truly depends on actin remodeling.
-
Octenidine (dihydrochloride) in Cell Assays
2026-08-13
Learn how Octenidine (dihydrochloride), SKU C6432, can be incorporated into reproducible antimicrobial, viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers formulation, controls, dose-response design, readout interference, and practical product-selection criteria.
-
Clasto-Lactacystin β-lactone in RIPK3 Assays
2026-08-13
Clasto-Lactacystin β-lactone provides an irreversible way to interrogate proteasome-dependent RIPK3 turnover. This article translates viral immune-evasion findings into practical assay logic, controls, and interpretation for ubiquitin-proteasome pathway research.
-
UTP Solution (100 mM) for RNA Assay Design
2026-08-12
Explore how UTP Solution supports controlled RNA synthesis, amplification, and nucleotide-sensitive assay workflows. This guide connects UTP handling with the TRIM66 olfactory receptor study to show how reagent quality and assay architecture shape biological interpretation.